Tern Plc further re. FundamentalVR fund raise

Tern plc

Tern plc (LON:TERN) noted this morning that in the Company’s announcement dated 11 August 2022, the Company stated that FVRVS Limited (“FundamentalVR”) had closed a second tranche of its Series B fund raising round, securing an additional £5 million in new investment (the “FundamentalVR Series B second tranche”) from a new institutional investor at the same valuation as the first tranche, making a total of £13.2 million raised in Series B funding at this time.

The Company notes that in its press release dated 11 August 2022, FundamentalVR, an independent privately held company, stated that it “has raised an additional $20 million to significantly accelerate medical skill-transfer and increase surgical proficiency through its world-leading medical simulation platform, Fundamental Surgery.”

Tern plc can confirm that all the information disclosed in its announcement dated 11 August 2022 is correct and understands that the figure of $20 million referred to by FundamentalVR includes committed contingent funding yet to be received by FundamentalVR. Such funding would be at the same valuation as the FundamentalVR Series B second tranche and would not affect the book value of Tern’s investment in FundamentalVR.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern notes automotive momentum at Device Authority

Tern Plc notes that Device Authority, in which it holds a 25.3% stake, has announced further progress in the automotive sector, securing a new OEM customer and expanding an existing Tier 1 deployment.

Key management emerges as a delivery risk in automotive software

Key management is becoming a delivery-critical constraint in software-defined vehicles, influencing risk, compliance and programme scalability.

Pharma teams gain early insight into message effectiveness

Talking Medicines gives pharma teams early insight into which messages resonate with healthcare professionals.

Talking Medicines joins 2026 UK AI Index

Talking Medicines joins the UK AI Index 2026, confirming its growing role in data-driven healthcare strategy.

AI in Healthcare 2025

In 2025, AI began reshaping healthcare delivery and marketing with practical applications, signalling a maturing investment landscape.

Talking Medicines targets messaging risk in pharma brand strategy

Talking Medicines reduces messaging risk for pharma brands by measuring real-time HCP response.

Search

Search